Here you will find our offers and requests for technology that are available for collaboration with companies. If you need any further information or have a particular technological issue to address, please contact us at firstname.lastname@example.org. We are open to different kinds of collaboration.
Quick method to assess if different isolates of M. Tuberculosis have the same clone origin and if they are resistant to rifampicin and isoniazid
Based in IS6110 (Gold standard), offers quick results (few hours), is automated, standardized and reproducible. If widely adopted, this technology would allow better control of TB. The technology can be used to identify strains resistant to rifampicin and isoniazid and can be extended to other bacteria with specific IS.
High reliability prediction of fluid/vascular responses and estimation of pleural pressure changes in patients
The non-invasive method allows the prediction of patient's response to intravenous administration of fluid or to evaluate the state of arterial tone or the change of pleural pressure due to respiration. It allows the optimization of hemodynamic monitoring. This evaluation can be carried out in patients under mechanical ventilation or in punctual monitoring, even in patients with cardiac or respiratory arrhythmias.
Differential diagnosis of non-tuberculous mycobacteria.
Method based in detection of immune response against non-TB mycobacteria by specific antigens in blood. It can be used for the differential diagnosis of NTM infections vs. tuberculosis (TB) infections or latent TB infection, allowing a more accurate diagnosis of latent TB particularly in the pediatric population (unmet need). This diagnosis is important in : pulmonary infections, lymphadenitis and skin and soft tissue infections, and specifically in: children diagnosed with cystic fibrosis, in patients suffering from chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) or in immunosuppressed adults.
Detection of Tuberculosis in urine samples by a specific metabolic signature.
A set of metabolic biomarkers, whose relative level can diagnose tuberculosis in urine samples. A quick and non invasive method to identify and classify patients with a high specificity and sensitivity and with a tuberculosis predictive value of 100%.
Personalised control and prevention of progression of COPD by a scientific expert system.
Expert system (algorithm transformed into software) created from an integrative approach based in published broad analysis of more than 200 variables in broad cohorts of patients and enriched with diverse public data sources at different levels . The product, a mobile application, is designed to help COPD patients to self manage in a personalised way their disease- control, prevention of progression, prevention in risks’ exposure and adherence to treatment’s maintenance.
Early prognosis of Tako-Tsubo cardiomyopathy in patients with aneurysmal subarachnoid haemorrhage.
Combined quantification of molecules in blood able of predict, with 100% efficiency from admission in emergency, if a patient with aneurysmal subarachnoid haemorrhage will develop Tako-Tsubo cardiomyopathy.
Mortality prediction in COVID-19 patients.
Quantification of a Coronavirus structural protein in plasma, serum or blood samples that enables to differentiate patients with bad prognosis and/or higher mortality risk candidates for receiving an antiviral therapy or further monitoring.